Pipeline

NKGen Biotech is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with cancer and neurodegenerative conditions.

SNK01, NKGen Biotech’s first cell therapy candidate, has planned clinical trials in several therapeutic areas, including oncology and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas.

Product

Discovery

Preclinical

Phase I

Phase II

Phase III

SNK01

– Refractory Solid Tumors, Phase l
– Neurodegenerative Disease, Phase l
– Localized/ Metastatic Sarcoma* – orphan, Phase l
– Triple Negative Breast Cancer*, Phase l

Refractory Solid Tumors

Neurodegenerative Disease

Localized/Metastatic Sarcoma¹ - Orphan

Triple Negative Breast Cancer¹

SNK01 +

pembrolizumab

– Stage IV Non-small Cell Lung Cancer, Phase ll

avelumab or pembrolizumab

– Refractory PD-L1+ AND PD-L1- Solid Tumors 2, Phase l

trastuzumab or cetuximab

– Refractory HER2+ OR EGFR+ Solid Tumors, Phase ll

AFM24

– EGFR+ Solid Tumors, Phase l

Stage IV Non- Small Cell Lung Cancer

Refractory PD-L1+ and PD-L1- Solid Tumors ²

Refractory HER2+ or EGFR+ Solid Tumors

EGFR+ Solid Tumors

Allogeneic SNK

Not Disclosed

¹ Following the completion of our Phase 1 trial and FDA comparability approval, we intend to initiate Phase 2 clinical trials in stage I-III negative breast cancer and localized/metastatic sarcoma.
² Following the data from our Phase 1 trial, with FDA consent, we expanded the Phase 1 trial to include a fourth cohort in refractory tumors with SNK in combination with avelumab or pembrolizumab.